Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP827898.RAzGpTL3_rFKoG7_Y56AKJ9w-Tr8ZUNN__2h22DaPNDVc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP827898.RAzGpTL3_rFKoG7_Y56AKJ9w-Tr8ZUNN__2h22DaPNDVc130_assertion type Assertion NP827898.RAzGpTL3_rFKoG7_Y56AKJ9w-Tr8ZUNN__2h22DaPNDVc130_head.
- NP827898.RAzGpTL3_rFKoG7_Y56AKJ9w-Tr8ZUNN__2h22DaPNDVc130_assertion description "[In this study we investigate effects of sulindac (the non-selective COX inhibitor), aspirin (the irreversible, preferential COX-1 inhibitor), NS-398 (the selective COX-2 inhibitor), NDGA (nordihydroguaiaretic acid, the selective LOX inhibitor) and ETYA (5,8,11,14-eicosatetraynoic acid, the COX and LOX inhibitor) on cell viability, MMP-2 and MMP-9 activities, and in vitro invasion of cancer cells derived from primary and metastatic head and neck, and colon cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP827898.RAzGpTL3_rFKoG7_Y56AKJ9w-Tr8ZUNN__2h22DaPNDVc130_provenance.
- NP827898.RAzGpTL3_rFKoG7_Y56AKJ9w-Tr8ZUNN__2h22DaPNDVc130_assertion evidence source_evidence_literature NP827898.RAzGpTL3_rFKoG7_Y56AKJ9w-Tr8ZUNN__2h22DaPNDVc130_provenance.
- NP827898.RAzGpTL3_rFKoG7_Y56AKJ9w-Tr8ZUNN__2h22DaPNDVc130_assertion SIO_000772 20654727 NP827898.RAzGpTL3_rFKoG7_Y56AKJ9w-Tr8ZUNN__2h22DaPNDVc130_provenance.
- NP827898.RAzGpTL3_rFKoG7_Y56AKJ9w-Tr8ZUNN__2h22DaPNDVc130_assertion wasDerivedFrom befree-2016 NP827898.RAzGpTL3_rFKoG7_Y56AKJ9w-Tr8ZUNN__2h22DaPNDVc130_provenance.
- NP827898.RAzGpTL3_rFKoG7_Y56AKJ9w-Tr8ZUNN__2h22DaPNDVc130_assertion wasGeneratedBy ECO_0000203 NP827898.RAzGpTL3_rFKoG7_Y56AKJ9w-Tr8ZUNN__2h22DaPNDVc130_provenance.